CapMan Life Science IV fund closes at EUR 54 million
CapMan Life Science IV fund held its final closing today at EUR 54 million. This makes the fund the largest life science fund managed by CapMan so far.
The fund invests in medical technology and service companies predominantly in the Nordic region.
A total of eight institutional investors joined CapMan Life Science IV, where two represented new investors in CapMan funds. CapMan Plc’s own commitment to the fund is EUR 10 million.
The fund has already made investments in three companies. Neoventa Medical AB is specialised in fetal monitoring in perinatal healthcare, ProstaLund AB manufactures devices for treatment of benign prostatic hyperplasia and QuickCool AB develops a new method for quick cooling of the brain to prevent brain damage.
Read more